Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineAdverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease

A study in the Annals of Internal Medicine looked at the association between cardiovascular outcomes and the coprescription of nitrates with PDE5 inhibitors in more than 42,000 men over a 10-year period. Two composite outcomes were measured: 1) cardiac arrest, shock, myocardial infarction, ischemic stroke, or acute coronary arteriography; and 2) syncope, angina pectoris, or drug-related adverse event. The authors found no statistically significant increase in measured cardiovascular AEs.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form